Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
BioAmber
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Developer and producer of green chemicals from agricultural feedstocks with a focus on bio-based succinic acid

Founded in 2008
Founded in

Company type Bankrupt Public (BIOA)
Company type

Industry Group materials & chemicals

Sector fuels & chemicals

TRL Range 7-8
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Montreal, QC Montreal, Canada
Address
City
State
Zip
Country

Parent Companies

Website

Updated by Cleantech Group on 05/07/2020

Traction
  • 1 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
10/02/2014

Xuchuan Chemical Xuchuan Chemical

BioAmber will supply bio-succinic acid to Xuchuan Chemical to produce cast polyurethane elastomers.

Confirmed by Xuchuan Chemical
Delete
Partnerships
Save
Add Partnership
Date Partner Type
04/18/2016
Comet Biorefining Comet Biorefining
The deal includes provisions for Comet to supply dextrose to future BioAmber manufacturing facilities and provides BioAmber with certain exclusive rights in the fields of succinic acid, 1,4-butanediol (BDO) and tetrahydrofun (THF). This partnership is the culmination of development work as part of BioIndustrial Innovation Canada's recently completed cellulosic sugar study.
View source    
Confirmed by Comet Biorefining
Technology Partner
Delete
Investment Rounds
Save

IPO INFORMATION

Date

05/10/2013

IPO status

Listed

IPO Type

IPO

Amount

$80M

Initial shares

8000000

Ticker symbol

BIOA

Exchange listed

NYSE

Prospectus URL

Prospectus

Source URL

Source

Description

BioAmber announced the pricing of its initial public offering of 8 million units, at $10 per unit. The Units are expected to trade on the NYSE under the symbol BIOAU.

Cancel Save
Add Investment
Date Investors Type Amount
01/24/2017 (0)
Post-money valuation of
BioAmber has announced that due to strong demand, the underwriters have agreed to purchase 3,684,212 shares of common stock of the Company, together with warrants to purchase 1,842,106 shares of common stock of the Company with an exercise price of US$5.50 per share.
 Follow-on Public Offering $17,500,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font